A systematic review of studies describing the monitoring of CA125 increments in patients with advanced ovarian cancer during the follow-up period after the first-line chemotherapy showed that the median sensitivity was 85% (range 62–93%) [254]. This evidence concerns the gene MUC16 and ovarian carcinoma.